Alzinova AB(DE:78D)
€0.01+0.00 (+8.33%)
DE:78D
Alzinova AB stock drug pipeline
€0.01
At close:+0.00 (+8.33%)
Alzinova AB (78D) Drug Pipeline
0 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Alz-101 | Alzheimer Disease, Dementia Alzheimers, Dementia, Mild | Phase I | Completed | A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease | Mar 25, 2022 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Alz-101 | Phase I | Alzheimer Disease, Dementia Alzheimers, Dementia, Mild | Completed | A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease | Mar 25, 2022 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Alzinova AB (DE:78D) have in its pipeline
Alzinova AB DE:78D is currently developing the following drugs: Alz-101. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

